These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32860480)

  • 21. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
    Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
    J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
    Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
    Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study.
    Hafner A; Ghislain PD; Kovács R; Batchelor R; Katoulis AC; Kirby B; Banayan H; Schonbrun M
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2277-2284. PubMed ID: 34320249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.
    Heidari A; Ghane Y; Heidari N; Sadeghi S; Goodarzi A
    Int Immunopharmacol; 2024 Jan; 127():111435. PubMed ID: 38150881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    Clin Exp Dermatol; 2021 Mar; 46(2):306-313. PubMed ID: 32931599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version.
    Zouboulis CC; Bechara FG; Fritz K; Goebeler M; Hetzer FH; Just E; Kirsten N; Kokolakis G; Kurzen H; Nikolakis G; Pinter A; Podda M; Rosinski K; Schneider-Burrus S; Taube KM; Volz T; Winkler T; Kristandt A; Presser D; Zouboulis VA
    J Dtsch Dermatol Ges; 2024 Jun; 22(6):868-889. PubMed ID: 38770982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.
    Odorici G; Pacetti L; Forconi R; Schettini N; Zedde P; Corazza M; Bettoli V
    J Dermatolog Treat; 2022 Jun; 33(4):2063-2067. PubMed ID: 33843413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologic Treatment for Hidradenitis Suppurativa.
    Flood KS; Porter ML; Kimball AB
    Am J Clin Dermatol; 2019 Oct; 20(5):625-638. PubMed ID: 31140067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
    Frew JW; Navrazhina K; Grand D; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Ungar J; Krueger JG
    J Am Acad Dermatol; 2020 Nov; 83(5):1341-1348. PubMed ID: 32416208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients.
    Nazzaro G; Calzari P; Passoni E; Vaienti S; Moltrasio C; Barbareschi M; Muratori S; Veraldi S; Marzano AV
    Dermatol Ther; 2021 Jan; 34(1):e14706. PubMed ID: 33368976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
    Zouboulis CC; Tzellos T; Kyrgidis A; Jemec GBE; Bechara FG; Giamarellos-Bourboulis EJ; Ingram JR; Kanni T; Karagiannidis I; Martorell A; Matusiak Ł; Pinter A; Prens EP; Presser D; Schneider-Burrus S; von Stebut E; Szepietowski JC; van der Zee HH; Wilden SM; Sabat R;
    Br J Dermatol; 2017 Nov; 177(5):1401-1409. PubMed ID: 28636793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems.
    Włodarek K; Stefaniak A; Matusiak Ł; Szepietowski JC
    Dermatology; 2020; 236(1):8-14. PubMed ID: 31487719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
    Roccuzzo G; Rozzo G; Burzi L; Repetto F; Dapavo P; Ribero S; Quaglino P
    Dermatol Ther; 2022 Nov; 35(11):e15803. PubMed ID: 36062429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial.
    Ben Abdallah H; Bregnhøj A; Emmanuel T; Ghatnekar G; Johansen C; Iversen L
    JAMA Dermatol; 2024 Jan; 160(1):63-70. PubMed ID: 38055242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.
    Daoud M; Suppa M; Benhadou F; Daxhelet M; Njimi H; White J; Jemec G; Del Marmol V
    Front Med (Lausanne); 2023; 10():1145152. PubMed ID: 37138732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
    Marzano AV; Genovese G; Casazza G; Moltrasio C; Dapavo P; Micali G; Sirna R; Gisondi P; Patrizi A; Dini V; Bianchini D; Bianchi L; Fania L; Prignano F; Offidani A; Atzori L; Bettoli V; Cannavò SP; Venturini M; Bongiorno MR; Costanzo A; Fabbrocini G; Peris K
    Br J Dermatol; 2021 Jan; 184(1):133-140. PubMed ID: 32119111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa.
    Jepsen R; Edwards C; Flora A; Kozera E; Frew JW
    J Am Acad Dermatol; 2023 Oct; 89(4):694-702. PubMed ID: 37307994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES; Garnock-Jones KP; Keam SJ
    Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting.
    Aarts P; van Huijstee JC; van der Zee HH; van Doorn MBA; van Straalen KR; Prens EP
    J Am Acad Dermatol; 2023 Oct; 89(4):677-684. PubMed ID: 37116615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.